CN114080231B - 用于鉴定特异性攻击癌细胞的t细胞的特异性标记 - Google Patents

用于鉴定特异性攻击癌细胞的t细胞的特异性标记 Download PDF

Info

Publication number
CN114080231B
CN114080231B CN202080049198.6A CN202080049198A CN114080231B CN 114080231 B CN114080231 B CN 114080231B CN 202080049198 A CN202080049198 A CN 202080049198A CN 114080231 B CN114080231 B CN 114080231B
Authority
CN
China
Prior art keywords
cells
cell
tcr
cancer
subpopulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080049198.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114080231A (zh
Inventor
冨樫庸介
西川博嘉
山下和男
N·C·P·萨克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hongtai Biotechnology Co ltd
National Cancer Center Japan
Original Assignee
Hongtai Biotechnology Co ltd
National Cancer Center Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hongtai Biotechnology Co ltd, National Cancer Center Japan filed Critical Hongtai Biotechnology Co ltd
Publication of CN114080231A publication Critical patent/CN114080231A/zh
Application granted granted Critical
Publication of CN114080231B publication Critical patent/CN114080231B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080049198.6A 2019-07-10 2020-07-09 用于鉴定特异性攻击癌细胞的t细胞的特异性标记 Active CN114080231B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-128517 2019-07-10
JP2019128517 2019-07-10
PCT/JP2020/026897 WO2021006316A1 (ja) 2019-07-10 2020-07-09 がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー

Publications (2)

Publication Number Publication Date
CN114080231A CN114080231A (zh) 2022-02-22
CN114080231B true CN114080231B (zh) 2025-02-14

Family

ID=74114521

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080049198.6A Active CN114080231B (zh) 2019-07-10 2020-07-09 用于鉴定特异性攻击癌细胞的t细胞的特异性标记

Country Status (5)

Country Link
US (1) US20220257656A1 (https=)
EP (1) EP3998082A4 (https=)
JP (1) JP7640047B2 (https=)
CN (1) CN114080231B (https=)
WO (1) WO2021006316A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240052309A1 (en) * 2021-01-04 2024-02-15 Thyas Co. Ltd. Method for producing regenerated t cell via ips cell
WO2025141875A1 (ja) * 2023-12-28 2025-07-03 国立大学法人三重大学 腫瘍反応性ｔ細胞の製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105163744A (zh) * 2013-03-01 2015-12-16 美国卫生和人力服务部 从肿瘤中产生肿瘤反应性t细胞的富集群的方法
WO2018226336A1 (en) * 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
WO2019084493A1 (en) * 2017-10-27 2019-05-02 The Trustees Of The University Of Pennsylvania METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SUSPECTED T CELLS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58168464A (ja) 1982-03-30 1983-10-04 Kobe Steel Ltd 類似鋼種の多連連続鋳造法
EP2203746B1 (en) * 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
CN102539736B (zh) * 2011-12-16 2015-04-29 北京汉氏联合生物技术有限公司 一种cd106阳性细胞、其鉴定、制备方法及应用
ES2946697T3 (es) * 2014-09-10 2023-07-24 Miltenyi Biotec Bv & Co Kg Una población celular para su uso en el tratamiento de cáncer
SG11201803419PA (en) 2015-10-30 2018-05-30 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
JOP20190224A1 (ar) * 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
CN109777872B (zh) * 2017-11-15 2021-04-02 北京大学 肺癌中的t细胞亚群及其特征基因
JP2019128517A (ja) 2018-01-26 2019-08-01 ソニーセミコンダクタソリューションズ株式会社 撮像装置、及び、電子機器
CA3171559A1 (en) * 2020-03-20 2021-09-23 Sri Krishna Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105163744A (zh) * 2013-03-01 2015-12-16 美国卫生和人力服务部 从肿瘤中产生肿瘤反应性t细胞的富集群的方法
WO2018226336A1 (en) * 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
WO2019084493A1 (en) * 2017-10-27 2019-05-02 The Trustees Of The University Of Pennsylvania METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SUSPECTED T CELLS

Also Published As

Publication number Publication date
EP3998082A1 (en) 2022-05-18
WO2021006316A1 (ja) 2021-01-14
CN114080231A (zh) 2022-02-22
EP3998082A4 (en) 2024-02-07
US20220257656A1 (en) 2022-08-18
JP7640047B2 (ja) 2025-03-05
JPWO2021006316A1 (https=) 2021-01-14

Similar Documents

Publication Publication Date Title
Duraiswamy et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
Pereira et al. Sestrins induce natural killer function in senescent-like CD8+ T cells
Li et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells
Harlin et al. Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites
Matoba et al. Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer
JP7760374B2 (ja) Ｔ細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
Zhang et al. Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
Shah et al. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes
Chatani et al. Cell surface marker-based capture of neoantigen-reactive CD8+ T-cell receptors from metastatic tumor digests
US20230138309A1 (en) Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy
Ziblat et al. Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
Mensink et al. Tregs from human blood differentiate into nonlymphoid tissue–resident effector cells upon TNFR2 costimulation
Debesset et al. TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion
Davies et al. Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
Chambers et al. Functional expression of CD73 on human natural killer cells
Stromnes et al. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer
CN114080231B (zh) 用于鉴定特异性攻击癌细胞的t细胞的特异性标记
Ibáñez-Molero et al. Tumour-reactive heterotypic CD8 T cell clusters from clinical samples
Luu et al. B7-H7 is inducible on T cells to regulate their immune response and serves as a marker for exhaustion
Bräunlein et al. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma
Walwyn-Brown et al. Phosphoantigen-Stimulated γδ T Cells Suppress Natural Killer–Cell Responses to Missing-Self
Campos-Mora et al. NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells
Li et al. Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer
Wang et al. Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade
Kwek et al. Identification and regulation of circulating tumor-TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant